Business
Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons ...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) SalesInitial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare NetworkToronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) (\"Therma Bright\" or the \"Company\"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients that had undergone specialized knee surgeries by trained surgeons with expertise in the procedure. Specialized knee surgeries represent a high value and growing segment of the U.S. healthcare market.\"We are pleased to partner with Therma Bright in offering the Venowave™ VW5 to our doctor network,\" shared Beau Wood, President, Gen-X Med. \"We've seen great patient success with the initial 200-unit purchase and anticipate placing additional orders as we ramp up awareness and adoption of this special vascular compression therapy solution.\"Rob Fia, CEO of Therma Bright, added, \"This partnership with Gen-X Med is a strategic step in expanding Venowave's presence into a focused and high-value market segment. We believe the Venowave™ offers significant advantages for patients and the U.S. healthcare system by reducing post-surgical complications and costly readmissions, which aligns with our mission to provide innovative and effective medical solutions that improve patient outcomes and create value.\"According to a November 2024 press announcement from Straits Research, the global compression therapy market was valued at $4.18 billion in 2024 and is projected to grow to $6.72 billion by 2033, representing a compound annual growth rate (CAGR) of 7.30% from 2025 to 2033.About the Venowave™ VW5The Venowave™ VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the FDA-designated Durable Medical Equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lympha...